Literature DB >> 24844406

Comparison of succinimidyl [(125)I]iodobenzoate with iodogen iodination methods to study pharmacokinetics and ADME of biotherapeutics.

Jianqing Chen1, Mengmeng Wang, Alison Joyce, David DeFranco, Mania Kavosi, Xin Xu, Denise M O'Hara.   

Abstract

PURPOSE: To assess the application of succinimidyl iodobenzoate (SIB) iodination method in labeling biotherapeutics to study their pharmacokinetics (PK) and biodistribution.
METHOD: An IgG molecule (protein-01) and a 40 KDa protein (protein-02) were evaluated. Pharmacokinetics (PK) and biodistribution of the radiolabeled IgG ((125)I-protein-01) in mice compared parameters from SIB and Iodogen protein iodination labeling methods. In addition, PK of radiolabeled 40 KDa protein ((125)I-protein-02) using SIB was compared with non-labeled protein-02 analyzed by ligand binding assay (LBA).
RESULTS: Up to 72 h following a single IP injection to mice, the percentage of "free-label" determined by the soluble counts after TCA precipitation to total radioactivity in serum samples was 2.8-49.4% vs. <1.0% for (125)I-protein-01 iodinated via Iodogen or SIB methods, respectively, suggesting a higher in vivo stability of (125)I-protein-01 labeled via the SIB method. The serum exposure of (125)I-protein-01 was two-fold higher, and correspondingly, the tissue exposure was also higher (averaging 3.6 fold at 168 h) when using SIB protein labeling method than when using the Iodogen method. In addition, following subcutaneous (SC) administration to mice, the serum exposure of (125)I-protein-02 labeled via SIB method was similar to protein-02 measure by LBA.
CONCLUSION: In this study, iodination of proteins using SIB methodology has overcome the dehalogenation problem in vivo which is inherent in Iodogen method, and PK parameters of a protein iodinated via SIB were comparable to the un-labeled protein measured by LBA. The SIB iodination method is an improved labeling approach for biotherapeutics used in studying PK and biodistribution characteristics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24844406     DOI: 10.1007/s11095-014-1378-3

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  25 in total

1.  Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules.

Authors:  Binodh DeSilva; Wendell Smith; Russell Weiner; Marian Kelley; JoMarie Smolec; Ben Lee; Masood Khan; Richard Tacey; Howard Hill; Abbie Celniker
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

Review 2.  Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents.

Authors:  Denise M O'Hara; Valerie Theobald; Adrienne Clements Egan; Joel Usansky; Murli Krishna; Julie TerWee; Mauricio Maia; Frank P Spriggs; John Kenney; Afshin Safavi; Jeannine Keefe
Journal:  AAPS J       Date:  2012-03-14       Impact factor: 4.009

3.  Biodistribution of [125I]-labeled therapeutic proteins: application in protein drug development beyond oncology.

Authors:  Yulia Vugmeyster; David DeFranco; Pamela Szklut; Qin Wang; Xin Xu
Journal:  J Pharm Sci       Date:  2010-02       Impact factor: 3.534

4.  Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.

Authors:  R M Sharkey; T M Behr; M J Mattes; R Stein; G L Griffiths; L B Shih; H J Hansen; R D Blumenthal; R M Dunn; M E Juweid; D M Goldenberg
Journal:  Cancer Immunol Immunother       Date:  1997-05       Impact factor: 6.968

5.  Development of a stable radioiodinating reagent to label monoclonal antibodies for radiotherapy of cancer.

Authors:  D S Wilbur; S W Hadley; M D Hylarides; P G Abrams; P A Beaumier; A C Morgan; J M Reno; A R Fritzberg
Journal:  J Nucl Med       Date:  1989-02       Impact factor: 10.057

6.  Optimization of radioiodination and biotinylation of monoclonal antibody chimeric BR96: an indirect labeling using N-succinimidyl-3-(tri-n-butylstannyl)benzoate conjugate.

Authors:  J Chen; S E Strand; H O Sjögren
Journal:  Cancer Biother Radiopharm       Date:  1996-06       Impact factor: 3.099

7.  Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN.

Authors:  G W Visser; R P Klok; J W Gebbinck; T ter Linden; G A van Dongen; C F Molthoff
Journal:  J Nucl Med       Date:  2001-03       Impact factor: 10.057

8.  Alpha-melanocyte-stimulating hormone peptide analogs labeled with technetium-99m and indium-111 for malignant melanoma targeting.

Authors:  JianQing Chen; Zhen Cheng; Yubin Miao; Silvia S Jurisson; Thomas P Quinn
Journal:  Cancer       Date:  2002-02-15       Impact factor: 6.860

9.  Trichloroacetic acid-induced protein precipitation involves the reversible association of a stable partially structured intermediate.

Authors:  Dakshinamurthy Rajalingam; Charles Loftis; Jiashou J Xu; Thallapuranam Krishnaswamy S Kumar
Journal:  Protein Sci       Date:  2009-05       Impact factor: 6.725

10.  Rat liver iodothyronine monodeiodinase. Evaluation of the iodothyronine ligand-binding site.

Authors:  J Koehrle; M Auf'mkolk; H Rokos; R D Hesch; V Cody
Journal:  J Biol Chem       Date:  1986-09-05       Impact factor: 5.157

View more
  4 in total

1.  Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies.

Authors:  Lindsay B Avery; Mengmeng Wang; Mania S Kavosi; Alison Joyce; Jeffrey C Kurz; Yao-Yun Fan; Martin E Dowty; Minlei Zhang; Yiqun Zhang; Aili Cheng; Fei Hua; Hannah M Jones; Hendrik Neubert; Robert J Polzer; Denise M O'Hara
Journal:  MAbs       Date:  2016-05-27       Impact factor: 5.857

2.  Site-Specific Radioiodination of Oligonucleotides with a Phenolic Element in a Programmable Approach.

Authors:  Haitao Zhao; Yu Qin; Dunfang Liu; Xinyao Geng; Cheng Wang; Ding Ding; Xuan Ding; Qian Xia; Jianjun Liu; Ruowen Wang; Weihong Tan
Journal:  Molecules       Date:  2022-09-23       Impact factor: 4.927

3.  Radioimmunotherapy for CD133(+) colonic cancer stem cells inhibits tumor development in nude mice.

Authors:  Dinghu Weng; Xueyan Jin; Saimei Qin; Xiaoli Lan; Chong Chen; Xun Sun; Xianliang She; Changling Dong; Rui An
Journal:  Oncotarget       Date:  2017-07-04

4.  Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models.

Authors:  Taiki Kurino; Reiko Matsuda; Ayu Terui; Hiroyuki Suzuki; Tomomi Kokubo; Tomoya Uehara; Yasushi Arano; Akihiro Hisaka; Hiroto Hatakeyama
Journal:  J Immunother Cancer       Date:  2020-02       Impact factor: 13.751

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.